These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 36271897)

  • 1. Preemptive cyclosporin A in immune-mediated thrombotic thrombocytopenic purpura.
    Comparon C; Galicier L; Rebibou JM; Coppo P; Benhamou Y
    Eur J Haematol; 2023 Feb; 110(2):157-160. PubMed ID: 36271897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura.
    Jestin M; Benhamou Y; Schelpe AS; Roose E; Provôt F; Galicier L; Hié M; Presne C; Poullin P; Wynckel A; Saheb S; Deligny C; Servais A; Girault S; Delmas Y; Kanouni T; Lautrette A; Chauveau D; Mousson C; Perez P; Halimi JM; Charvet-Rumpler A; Hamidou M; Cathébras P; Vanhoorelbeke K; Veyradier A; Coppo P;
    Blood; 2018 Nov; 132(20):2143-2153. PubMed ID: 30201758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy.
    Joly BS; Stepanian A; Leblanc T; Hajage D; Chambost H; Harambat J; Fouyssac F; Guigonis V; Leverger G; Ulinski T; Kwon T; Loirat C; Coppo P; Veyradier A;
    Lancet Haematol; 2016 Nov; 3(11):e537-e546. PubMed ID: 27720178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful preventive treatment with cyclosporine in a patient with relapsed/refractory immune-mediated thrombotic thrombocytopenic purpura: a case report and review of the literature.
    Uchino K; Sakai K; Shinohara S; Matsuhisa A; Iida Y; Nakano Y; Matsumura S; Kanasugi J; Takasugi S; Nakamura A; Horio T; Murakami S; Mizuno S; Yamamoto H; Hanamura I; Matsumoto M; Takami A
    Int J Hematol; 2022 Aug; 116(2):295-301. PubMed ID: 35274194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura.
    Hie M; Gay J; Galicier L; Provôt F; Presne C; Poullin P; Bonmarchand G; Wynckel A; Benhamou Y; Vanhille P; Servais A; Bordessoule D; Coindre JP; Hamidou M; Vernant JP; Veyradier A; Coppo P;
    Blood; 2014 Jul; 124(2):204-10. PubMed ID: 24869941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relapse Rate in Survivors of Acute Autoimmune Thrombotic Thrombocytopenic Purpura Treated with or without Rituximab.
    Falter T; Herold S; Weyer-Elberich V; Scheiner C; Schmitt V; von Auer C; Messmer X; Wild P; Lackner KJ; Lämmle B; Scharrer I
    Thromb Haemost; 2018 Oct; 118(10):1743-1751. PubMed ID: 30235478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies.
    Bresin E; Gastoldi S; Daina E; Belotti D; Pogliani E; Perseghin P; Scalzulli PR; Paolini R; Marcenò R; Remuzzi G; Galbusera M
    Thromb Haemost; 2009 Feb; 101(2):233-8. PubMed ID: 19190804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term risk of relapse in immune-mediated thrombotic thrombocytopenic purpura and the role of anti-CD20 therapy.
    Doyle AJ; Stubbs MJ; Dutt T; Lester W; Thomas W; van Veen J; Hermans J; Cranfield T; Hill QA; Clark A; Bagot C; Austin S; Westwood JP; Thomas M; Scully M
    Blood; 2023 Jan; 141(3):285-294. PubMed ID: 36322971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of prophylactic cyclosporine therapy on ADAMTS13 biomarkers in patients with idiopathic thrombotic thrombocytopenic purpura.
    Cataland SR; Jin M; Lin S; Kraut EH; George JN; Wu HM
    Am J Hematol; 2008 Dec; 83(12):911-5. PubMed ID: 18821711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of relapse and preventative strategies in immune thrombotic thrombocytopenic purpura.
    Pavenski K; Huang SS; Patriquin CJ
    Expert Rev Hematol; 2021 Nov; 14(11):1027-1040. PubMed ID: 34747320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of obinutuzumab and ofatumumab in the treatment of immune thrombotic thrombocytopenic purpura.
    Doyle AJ; Stubbs MJ; Lester W; Thomas W; Westwood JP; Thomas M; Percy C; Prasannan N; Scully M
    Br J Haematol; 2022 Jul; 198(2):391-396. PubMed ID: 35430727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases.
    Fakhouri F; Vernant JP; Veyradier A; Wolf M; Kaplanski G; Binaut R; Rieger M; Scheiflinger F; Poullin P; Deroure B; Delarue R; Lesavre P; Vanhille P; Hermine O; Remuzzi G; Grünfeld JP
    Blood; 2005 Sep; 106(6):1932-7. PubMed ID: 15933059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low levels of ADAMTS-13 with high anti-ADAMTS-13 antibodies during remission of immune-mediated thrombotic thrombocytopenic purpura highly predict for disease relapse: A multi-institutional study.
    Schieppati F; Russo L; Marchetti M; Barcella L; Cefis M; Gomez-Rosas P; Caldara G; Carpenedo M; D'Adda M; Rambaldi A; Savignano C; Billio A; Bruno Franco M; Toschi V; Falanga A
    Am J Hematol; 2020 Aug; 95(8):953-959. PubMed ID: 32350923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature.
    Elliott MA; Heit JA; Pruthi RK; Gastineau DA; Winters JL; Hook CC
    Eur J Haematol; 2009 Oct; 83(4):365-72. PubMed ID: 19508684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daratumumab for immune thrombotic thrombocytopenic purpura.
    van den Berg J; Kremer Hovinga JA; Pfleger C; Hegemann I; Stehle G; Holbro A; Studt JD
    Blood Adv; 2022 Feb; 6(3):993-997. PubMed ID: 34551063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab prolongs the time to relapse in patients with immune thrombotic thrombocytopenic purpura: analysis of off-label use in Japan.
    Kubo M; Sakai K; Yoshii Y; Hayakawa M; Matsumoto M
    Int J Hematol; 2020 Dec; 112(6):764-772. PubMed ID: 32856231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of thrombotic thrombocytopenic purpura.
    Coppo P;
    Transfus Clin Biol; 2017 Sep; 24(3):148-153. PubMed ID: 28645643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naturally Occurring Anti-Idiotypic Antibodies Portray a Largely Private Repertoire in Immune-Mediated Thrombotic Thrombocytopenic Purpura.
    Heeb SR; Schaller M; Kremer Hovinga JA
    J Immunol; 2022 Jun; 208(11):2497-2507. PubMed ID: 35589126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence, diagnosis, and outcome of immune-mediated thrombotic thrombocytopenic purpura: A nationwide survey by the Spanish registry of thrombotic thrombocytopenic purpura.
    Pascual-Izquierdo C; Del Rio-Garma J; de la Rubia J; Viejo A; Mingot E; Cid J; Solanich X; Fernández-Sojo J; Martín-Sánchez J; Hernández L; García-Gala JM; Alonso N; González V; Oliva A; Gómez-Seguí I; Goterris R; Guerra L; García-Candel F; Fernández-Docampo M; Antelo ML; Salgado-Barreira Á; Salinas R;
    J Clin Apher; 2021 Aug; 36(4):563-573. PubMed ID: 33780553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case of severe ADAMTS13 deficiency presenting as thrombotic thrombocytopenic purpura in pregnancy.
    Nikolaou M; Karakantza M; Adonakis G; Theodorou G; Zoumbos N; Decavalas G
    Med Pregl; 2012; 65(9-10):436-9. PubMed ID: 23214340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.